DK1910521T3 - Generering af allo-begrænsede, antigenspecifikke T-celler - Google Patents
Generering af allo-begrænsede, antigenspecifikke T-cellerInfo
- Publication number
- DK1910521T3 DK1910521T3 DK06776623.8T DK06776623T DK1910521T3 DK 1910521 T3 DK1910521 T3 DK 1910521T3 DK 06776623 T DK06776623 T DK 06776623T DK 1910521 T3 DK1910521 T3 DK 1910521T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- specific
- antigen
- allo
- generation
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017128 | 2005-08-05 | ||
| EP06007539 | 2006-04-10 | ||
| PCT/EP2006/007752 WO2007017201A1 (en) | 2005-08-05 | 2006-08-04 | Generation of antigen specific t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1910521T3 true DK1910521T3 (da) | 2011-02-07 |
Family
ID=37598202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10179257.0T DK2327763T3 (da) | 2005-08-05 | 2006-08-04 | Antigen generation af specifikke T-celler |
| DK06776623.8T DK1910521T3 (da) | 2005-08-05 | 2006-08-04 | Generering af allo-begrænsede, antigenspecifikke T-celler |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10179257.0T DK2327763T3 (da) | 2005-08-05 | 2006-08-04 | Antigen generation af specifikke T-celler |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8486694B2 (da) |
| EP (3) | EP2327763B1 (da) |
| JP (3) | JP5079697B2 (da) |
| AT (1) | ATE484578T1 (da) |
| DE (1) | DE602006017556D1 (da) |
| DK (2) | DK2327763T3 (da) |
| ES (2) | ES2672895T3 (da) |
| HU (1) | HUE038833T2 (da) |
| PL (1) | PL2327763T3 (da) |
| PT (1) | PT2327763T (da) |
| WO (1) | WO2007017201A1 (da) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| US8486694B2 (en) * | 2005-08-05 | 2013-07-16 | Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH | Generation of antigen specific T cells |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| DK2352756T3 (da) | 2008-11-24 | 2012-12-03 | Helmholtz Zentrum Muenchen | Højaffin T-cellereceptor og anvendelse af denne |
| CA2751762A1 (en) * | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP3213765B1 (en) * | 2010-09-20 | 2019-08-28 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| CA2848209C (en) * | 2011-09-15 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| EP3505537A1 (en) | 2012-05-07 | 2019-07-03 | Trustees of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| CN110241086A (zh) * | 2012-06-11 | 2019-09-17 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| EP2892544A4 (en) | 2012-09-05 | 2016-11-02 | Univ Virginia Patent Found | TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP3071686B1 (en) | 2013-11-22 | 2020-07-22 | Cellectis SA | Method for generating batches of allogeneic t-cells with averaged potency |
| MX2016012176A (es) * | 2014-03-20 | 2017-04-13 | H Lee Moffitt Cancer Ct & Res | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. |
| EP3137100B1 (en) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| EP3201321A1 (en) * | 2014-10-02 | 2017-08-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| CN107074932A (zh) * | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
| EP3215164A1 (en) | 2014-11-03 | 2017-09-13 | Immures S.r.l. | T cell receptors |
| KR20170075785A (ko) * | 2014-11-05 | 2017-07-03 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포 |
| US11001830B2 (en) * | 2015-03-16 | 2021-05-11 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library |
| CN108137688A (zh) | 2015-06-01 | 2018-06-08 | 基因医疗免疫疗法有限责任公司 | 产生抗t细胞受体的抗体的方法 |
| US10858760B2 (en) | 2015-06-01 | 2020-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| CN108472314A (zh) | 2015-07-31 | 2018-08-31 | 明尼苏达大学董事会 | 修饰的细胞和治疗方法 |
| IL257840B2 (en) * | 2015-09-15 | 2023-10-01 | Us Health | T cell receptors. The mutant acquaintances of K.R.A.S. limited to human leukocyte antigen - 8 |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| KR102319839B1 (ko) | 2015-12-23 | 2021-11-01 | 메디진 이뮤노테라피스 게엠바하 | 항원-특이적 tcr의 신규 생성 |
| JP7019578B2 (ja) * | 2015-12-30 | 2022-02-15 | セルジーン コーポレイション | Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球 |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| BR112019005633A8 (pt) * | 2016-09-23 | 2023-04-11 | Hutchinson Fred Cancer Res | Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos |
| AU2017346885B2 (en) | 2016-10-18 | 2021-10-21 | Intima Bioscience, Inc. | Tumor infiltrating lymphocytes and methods of therapy |
| WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| JP7181517B2 (ja) * | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| KR102490850B1 (ko) | 2018-02-26 | 2023-01-26 | 메디진 이뮤노테라피스 게엠바하 | Nyeso t 세포 수용체 |
| CA3112471A1 (en) * | 2018-09-10 | 2020-03-19 | Torque Therapeutics, Inc. | Antigen-specific t lymphocytes and methods of making and using the same |
| CA3113259A1 (en) * | 2018-09-27 | 2020-04-02 | Genocea Biosciences, Inc. | Treatment methods |
| WO2020123825A1 (en) * | 2018-12-12 | 2020-06-18 | The Brigham And Women's Hospital, Inc. | Compositions and methods for immunosuppression |
| TW202102530A (zh) | 2019-04-04 | 2021-01-16 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途 |
| JP7340144B2 (ja) * | 2019-10-02 | 2023-09-07 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| JP6878544B2 (ja) * | 2019-10-02 | 2021-05-26 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| CN115397863A (zh) | 2020-04-01 | 2022-11-25 | 基因医疗免疫疗法有限责任公司 | Cd3融合蛋白及其用途 |
| WO2022038115A1 (en) | 2020-08-18 | 2022-02-24 | Medigene Immunotherapies Gmbh | ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY |
| CA3193353A1 (en) | 2020-09-24 | 2022-03-31 | Carina WEHNER | Prame specific t-cell receptors and uses thereof |
| WO2023175069A1 (en) | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
| WO2023175070A1 (en) | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997026328A1 (en) * | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| EP1420253B1 (de) * | 2002-08-23 | 2006-05-31 | Deutsches Rheuma-Forschungszentrum Berlin | Verfahren zum Nachweis und zur Isolierung von T-Lymphozyten, die ein definiertes Antigen erkennen |
| US8486694B2 (en) * | 2005-08-05 | 2013-07-16 | Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH | Generation of antigen specific T cells |
-
2006
- 2006-08-04 US US11/990,054 patent/US8486694B2/en active Active
- 2006-08-04 HU HUE10179257A patent/HUE038833T2/hu unknown
- 2006-08-04 WO PCT/EP2006/007752 patent/WO2007017201A1/en active Application Filing
- 2006-08-04 JP JP2008524450A patent/JP5079697B2/ja active Active
- 2006-08-04 EP EP10179257.0A patent/EP2327763B1/en active Active
- 2006-08-04 AT AT06776623T patent/ATE484578T1/de active
- 2006-08-04 EP EP18161391.0A patent/EP3369812B1/en active Active
- 2006-08-04 DK DK10179257.0T patent/DK2327763T3/da active
- 2006-08-04 DE DE602006017556T patent/DE602006017556D1/de active Active
- 2006-08-04 DK DK06776623.8T patent/DK1910521T3/da active
- 2006-08-04 ES ES10179257T patent/ES2672895T3/es active Active
- 2006-08-04 EP EP06776623A patent/EP1910521B1/en active Active
- 2006-08-04 PL PL10179257T patent/PL2327763T3/pl unknown
- 2006-08-04 PT PT101792570T patent/PT2327763T/pt unknown
- 2006-08-04 ES ES18161391T patent/ES2842878T3/es active Active
-
2012
- 2012-07-10 JP JP2012154420A patent/JP2012213402A/ja active Pending
-
2013
- 2013-07-12 US US13/940,715 patent/US20140141026A1/en not_active Abandoned
-
2016
- 2016-02-05 JP JP2016020781A patent/JP2016135127A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3369812A1 (en) | 2018-09-05 |
| US20140141026A1 (en) | 2014-05-22 |
| JP5079697B2 (ja) | 2012-11-21 |
| EP1910521A1 (en) | 2008-04-16 |
| WO2007017201A1 (en) | 2007-02-15 |
| ATE484578T1 (de) | 2010-10-15 |
| JP2012213402A (ja) | 2012-11-08 |
| PL2327763T3 (pl) | 2018-08-31 |
| DE602006017556D1 (de) | 2010-11-25 |
| US8486694B2 (en) | 2013-07-16 |
| EP3369812B1 (en) | 2020-10-07 |
| EP2327763A1 (en) | 2011-06-01 |
| JP2009502185A (ja) | 2009-01-29 |
| US20100189728A1 (en) | 2010-07-29 |
| EP1910521B1 (en) | 2010-10-13 |
| DK2327763T3 (da) | 2018-05-22 |
| ES2842878T3 (es) | 2021-07-15 |
| EP2327763B1 (en) | 2018-03-14 |
| JP2016135127A (ja) | 2016-07-28 |
| PT2327763T (pt) | 2018-05-11 |
| HUE038833T2 (hu) | 2018-11-28 |
| ES2672895T3 (es) | 2018-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1910521T3 (da) | Generering af allo-begrænsede, antigenspecifikke T-celler | |
| Wolf et al. | Novel approaches to exploiting invariant NKT cells in cancer immunotherapy | |
| CY1121857T1 (el) | Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα | |
| Tian et al. | Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection | |
| Vatakis et al. | Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells | |
| Ryan et al. | Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation | |
| Jenq et al. | Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer | |
| Stephens et al. | Curing CNS autoimmune disease with myelin‐reactive Foxp3+ Treg | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| WO2005004592A8 (en) | Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications | |
| CY1110557T1 (el) | Αντισωματα ιντερλευκινης-10 | |
| CY1114047T1 (el) | Νεοι φορεις εκφρασης και χρησεις αυτων | |
| CY1114755T1 (el) | Ρυθμιση των τ κυτταρων | |
| Yee | Adoptive T cell therapy: addressing challenges in cancer immunotherapy | |
| BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
| DK1483294T3 (da) | Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse | |
| Yamaki et al. | OX40 and IL‐7 play synergistic roles in the homeostatic proliferation of effector memory CD4+ T cells | |
| DK1788078T3 (da) | Dendritisk celle-lægemiddel indeholdende den dendritiske celle, terapeutisk fremgangsmåde under anvendelse af den dendritiske celle og fremgangsmåde til dyrkning af gammadelta-T-celle | |
| Moon et al. | Use of epigenetic modification to induce FOXP3 expression in naïve T cells | |
| Pang et al. | Current progress of CAR-NK therapy in cancer treatment | |
| Sun et al. | Foxp3 regulates human natural CD4+ CD25+ regulatory T‐cell‐mediated suppression of xenogeneic response | |
| DK0952772T3 (da) | Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration | |
| Colonna et al. | Natural and expanded CD4+ CD25+ regulatory T cells in bone marrow transplantation | |
| BRPI0407002A (pt) | Células cultivadas que apresentam antìgeno cd14+ | |
| DK1572133T3 (da) | Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor |